8:00 am Check-In & Welcome Coffee
8:55 am Chair’s Opening Remarks
Enhancing Fusion Proteins: Leveraging Design Elements for Optimal Performance
9:00 am Protein Therapeutics Simplified: Next Generation Protein Modality as T-cell Engagers
Synopsis
- Our technology is designed to rapidly generate bispecific therapeutics with various novel and existing moieties such as nanobodies, scFvs, and non-antibody domains in a “LEGO”-like manner to generate TCEs
- The TCEs have very high safety profiles compared to conventional biologics and low pro-inflammatory cytokines
- In vivo efficacy has been demonstrated in NSCLC mouse models
9:30 am Exploring Fc-Fusion Design, Characterization & AI Integration for Improving Drug Discovery
Synopsis
- Harnessing the extracellular domain, explore Keros Therapeutics’ focus on molecular engineering
- Delve into design and characterization of Fc-fusion molecules
- Utilizing data insights to form strategic development for AI integration in drug discovery
10:00 am Morning Break & Refreshments
11:00 am Delve Into IgG and Fc Engineering, Specifically Focusing on Modulation of Antibodies interaction to FcgRIIB
Synopsis
- Consequence of engagement of IgG Fc by the inhibition FcgRIIB expressed by immune cells, non-immune cells and cancer cells.
- Binding characteristics of IgG Fc engineered for modulation of FcgRIIB interaction.
- Highlight on pre-clinical studies
11:30 am Targeting Erythropoietin Activity to a Subset of Receptor-Bearing Cells Via in Cis Binding to a Secondary Receptor
Synopsis
- Side effects can be undetectable at the right dose with a correctly targeted fusion protein
- Quantitative design specifications can guide molecular design • Cell-targeted drugs can be used to dissect molecular mechanisms
- A challenge for AI: A four-dimensional picture of the cell surface for fusion protein design
Navigating Therapeutic Competition: Strategies for Effective Product Differentiation in Challenging Landscapes
12:00 pm Panel Discussion: Strategies for Effective Product Differentiation in Competitive Therapeutic Landscapes
Synopsis
- Exploring challenges when developing different modalities for the same molecular pathway
- Discussing effective strategies, including considerations related to efficacy, safety, and unique features
- Recognizing the pivotal role of choices during clinical development and addressing unmet needs, while examining complexities in positioning products effectively in a competitive landscape
12:30 pm Lunch & Networking
Unveiling Developability Insights to Revolutionize Workflow Enhancement
1:30 pm Tuning the Stability of ADCs by Traversing the Formulation Design Space
Synopsis
- Simplifying workflow for ADC development through shared insights
- Addressing challenges and streamlining the development process for diverse antibodydrug conjugates
- Exploring the significance of analytical techniques in understanding ADC behavior
- Leveraging fundamental knowledge for advancing chemical and biological properties in ADC development
2:00 pm Navigating the Challenges of Multifunctional Platform Development
Synopsis
- Leveraging innovative technologies to enhance design flexibility
- Highlighting the impact of technology advancements on the profiles of multifunctional molecules
- Discussing the potential impact of multifunctional platforms on the biopharmaceutical industry
2:30 pm A Deep Dive into Strategies for Monoclonal & Multi-Specific Antibodies Developability
Synopsis
- Developing a comprehensive workflow for early research in monoclonal antibodies
- Leveraging data analytics to enhance the developability of antibodies and fusion proteins
- The impact of increased molecule variability on improving pipeline timelines and success rates
3:00 pm Afternoon Break & Refreshments
Innovative Strategies for Seamless Development: A Holistic Approach
4:00 pm Panel Discussion: Exploring Early Developability in Antibody & Fusion Protein Engineering
Synopsis
- Incorporating early developability assessments in the drug discovery process
- Overcoming challenges related to chemical and physical properties
- Exploring technology advancements in early developability assessments
- Discussing the evolving landscape of early developability assessments
Navigating the Testing Landscape: From Scaling Challenges to Strategic Decision-Making and Efficient Lead Characterization in Antibody Development
4:45 pm Decoding Proteomic Complexity: Harnessing Machine Learning for Precision in Biologics Discovery
Synopsis
- Uncover the unique methodology behind building machine learning models, enabling us to deconvolute complex protein pools for precise testing
- Learn how we utilize these models to unravel the intricate activity of protein pools, streamlining the identification of promising candidates
- Gain insights into the power of data-driven decision-making, a cornerstone in the journey from screening to lead optimization